AU2017261218A1 - Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxyacrylamide and uses thereof - Google Patents

Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxyacrylamide and uses thereof Download PDF

Info

Publication number
AU2017261218A1
AU2017261218A1 AU2017261218A AU2017261218A AU2017261218A1 AU 2017261218 A1 AU2017261218 A1 AU 2017261218A1 AU 2017261218 A AU2017261218 A AU 2017261218A AU 2017261218 A AU2017261218 A AU 2017261218A AU 2017261218 A1 AU2017261218 A1 AU 2017261218A1
Authority
AU
Australia
Prior art keywords
benzoimidazol
diethylamino
butyl
ethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017261218A
Other languages
English (en)
Inventor
David Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of AU2017261218A1 publication Critical patent/AU2017261218A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017261218A 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxyacrylamide and uses thereof Abandoned AU2017261218A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02
US62/330,673 2016-05-02
PCT/US2017/030414 WO2017192451A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Publications (1)

Publication Number Publication Date
AU2017261218A1 true AU2017261218A1 (en) 2018-11-29

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017261218A Abandoned AU2017261218A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxyacrylamide and uses thereof

Country Status (20)

Country Link
US (2) US10626092B2 (https=)
EP (2) EP3939966A1 (https=)
JP (1) JP2019514905A (https=)
KR (1) KR20190005904A (https=)
CN (1) CN109414425A (https=)
AR (1) AR108257A1 (https=)
AU (1) AU2017261218A1 (https=)
BR (1) BR112018072439A2 (https=)
CA (1) CA3022011A1 (https=)
CL (1) CL2018003109A1 (https=)
CO (1) CO2018012941A2 (https=)
EA (1) EA201892341A1 (https=)
ES (1) ES2886495T3 (https=)
IL (1) IL262578A (https=)
MA (1) MA44880A (https=)
MX (1) MX382095B (https=)
PH (1) PH12018502296B1 (https=)
SG (1) SG11201809471UA (https=)
TW (1) TW201741286A (https=)
WO (1) WO2017192451A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110291071B (zh) * 2017-02-28 2022-04-26 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
EP3728205A1 (en) 2017-12-19 2020-10-28 Assia Chemical Industries Ltd Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
WO2021217180A1 (en) 2020-04-22 2021-10-28 Johnson Matthey Public Limited Company Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
CA2135173A1 (en) 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
CA2355470C (en) 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
KR20020070285A (ko) 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
EP1162196A4 (en) 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP2005517007A (ja) 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
JP4429733B2 (ja) 2002-04-16 2010-03-10 帝人株式会社 Ｃｃｒ３拮抗作用を有するピペリジン誘導体
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
PT1673349E (pt) 2003-09-22 2010-09-28 S Bio Pte Ltd Derivados benzimidazole: preparação e aplicações farmacêuticas
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
ATE512953T1 (de) 2005-09-08 2011-07-15 S Heterocyclische verbindungen
CA2540459C (en) * 2005-09-08 2014-02-18 S*Bio Pte Ltd Benzimidazole compounds and uses in treating proliferative disorders
ES2703592T3 (es) 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
PT2914254T (pt) 2012-10-30 2020-04-02 Mei Pharma Inc Terapias de combinação para tratar cancros quimiorresistentes

Also Published As

Publication number Publication date
EP3452035A4 (en) 2019-09-25
EP3452035B1 (en) 2021-07-07
JP2019514905A (ja) 2019-06-06
MX382095B (es) 2025-03-13
WO2017192451A1 (en) 2017-11-09
CO2018012941A2 (es) 2018-12-28
EP3939966A1 (en) 2022-01-19
IL262578A (en) 2018-12-31
AR108257A1 (es) 2018-08-01
SG11201809471UA (en) 2018-11-29
US20200317621A1 (en) 2020-10-08
ES2886495T3 (es) 2021-12-20
CA3022011A1 (en) 2017-11-09
US10626092B2 (en) 2020-04-21
TW201741286A (zh) 2017-12-01
PH12018502296B1 (en) 2022-04-06
EP3452035A1 (en) 2019-03-13
EA201892341A1 (ru) 2019-05-31
CN109414425A (zh) 2019-03-01
BR112018072439A2 (pt) 2019-02-19
KR20190005904A (ko) 2019-01-16
US20190152923A1 (en) 2019-05-23
MA44880A (fr) 2021-03-17
CL2018003109A1 (es) 2019-04-26
MX2018013349A (es) 2019-02-20
PH12018502296A1 (en) 2019-07-08

Similar Documents

Publication Publication Date Title
JP7379680B2 (ja) テルフェニル化合物の新規な塩
AU2019268583B2 (en) Crystalline forms of a TLR7/TLR8 inhibitor
US20200317621A1 (en) Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof
JP6998655B2 (ja) 製造方法及びｍｄｍ２阻害剤の結晶形
JP7644027B2 (ja) Ｂｔｋ阻害剤の結晶形態
EP3218351B1 (en) A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377
JP2015522037A (ja) ベムラフェニブコリン塩の固体形態
JP2024518429A (ja) ４－［５－［（３ｓ）－３－アミノピロリジン－１－カルボニル］－２－［２－フルオロ－４－（２－ヒドロキシ－２－エチルプロピル）フェニル］フェニル］－２－フルオロ－ベンゾニトリルの塩の固体形態
US11566000B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
JP7068288B2 (ja) ４－（２－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール－６－イルオキシ）－ｎ－メチルピコリンアミドの結晶形
US8598201B2 (en) Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
US8710078B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
RU2828460C2 (ru) Кристаллические формы ингибитора btk
CN118525011A (zh) 一种吗啉基喹唑啉类化合物、其制备方法及应用
HK40061331B (en) Crystalline forms of a btk inhibitor
HK40061331A (en) Crystalline forms of a btk inhibitor
NZ620864B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
HK1192546B (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ POLYMORPHIC FORMS OF 3-(2-BUTYL-1-(2-DIETHYLAMINO-ETHYL)-1H-BENZOIMIDAZOL-5-YL)-N-HYDROXYACRYLAMIDE AND USES THEREOF

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application